MicroRNAs as clinical biomarkers and therapeutic tools in perioperative medicine

S Kreth, M Hübner, LC Hinske - Anesthesia & Analgesia, 2018 - journals.lww.com
RNA-induced silencing complex recognizes its target mRNA through Watson-Crick
complementarity of its 5′-end to the 3′-UTR of its target (Figure 1B). Whereas in plants …

MicroRNAs regulate bone development and regeneration

S Fang, Y Deng, P Gu, X Fan - International journal of molecular sciences, 2015 - mdpi.com
MicroRNAs (miRNAs) are endogenous small noncoding~ 22-nt RNAs, which have been
reported to play a crucial role in maintaining bone development and metabolism …

[HTML][HTML] Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects

D Neureiter, T Jäger, M Ocker… - World Journal of …, 2014 - ncbi.nlm.nih.gov
An improvement in pancreatic cancer treatment represents an urgent medical goal. Late
diagnosis and high intrinsic resistance to conventional chemotherapy has led to a dismal …

[HTML][HTML] Transcription factor RREB1: from target genes towards biological functions

YN Deng, Z Xia, P Zhang, S Ejaz… - International Journal of …, 2020 - ncbi.nlm.nih.gov
The Ras-responsive element binding protein 1 (RREB1) is a member of zinc finger
transcription factors, which is widely involved in biological processes including cell …

Alternative polyadenylation drives oncogenic gene expression in pancreatic ductal adenocarcinoma

S Venkat, AA Tisdale, JR Schwarz… - Genome …, 2020 - genome.cshlp.org
Alternative polyadenylation (APA) is a gene regulatory process that dictates mRNA 3′-UTR
length, resulting in changes in mRNA stability and localization. APA is frequently disrupted …

Noncoding RNAs: the shot callers in tumor immune escape

L Liu, Q Wang, Z Qiu, Y Kang, J Liu, S Ning… - Signal transduction and …, 2020 - nature.com
Immunotherapy, designed to exploit the functions of the host immune system against tumors,
has shown considerable potential against several malignancies. However, the utility of …

[HTML][HTML] Novel therapeutic targets for pancreatic cancer

SC Tang, YC Chen - World journal of gastroenterology: WJG, 2014 - ncbi.nlm.nih.gov
Pancreatic cancer has become the fourth leading cause of cancer death in the last two
decades. Only 3%-15% of patients diagnosed with pancreatic cancer had 5 year survival …

Non-coding RNAs in pancreatic cancer: challenges and opportunities for clinical application

V Taucher, H Mangge, J Haybaeck - Cellular Oncology, 2016 - Springer
Background Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with a dismal
prognosis for which new therapeutic strategies are desperately needed. Non-coding RNAs …

Non-coding RNAs in pancreatic ductal adenocarcinoma

R Gong, Y Jiang - Frontiers in oncology, 2020 - frontiersin.org
Non-coding RNAs (ncRNAs) are reported to be expressed in human cancers, including
pancreatic ductal adenocarcinoma (PDAC). These ncRNAs affect the growth, migration and …

MicroRNA-143 enhances chemosensitivity of Quercetin through autophagy inhibition via target GABARAPL1 in gastric cancer cells

F Du, Y Feng, J Fang, M Yang - Biomedicine & Pharmacotherapy, 2015 - Elsevier
MicroRNAs have emerged as fundamental regulators in gene expression through silencing
gene expression at the post-transcriptional and translational levels. In this study, miR-143 …